Bristol Myers Squibb Announced New Results From The Phase 3 DAYBREAK Open-label Extension Trial, Demonstrating The Long-term Efficacy And Safety Profile Of Zeposia (Ozanimod) In Patients With Relapsing Forms Of Multiple Sclerosis

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!